We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KWR:NYSEQuaker Houghton Analysis

Data as of 2026-08-10 - not real-time

$169.95

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The moving-average structure behind Quaker Chemical Corporation is bullish at $169.95, with short-term averages leading the long-term ones. Across the trailing 30 sessions it gained 8.5%. RSI sits at 64.5, which reads as approaching overbought, and MACD momentum is bullish. Recent trading has carved out support near $137.18 and resistance around $175.07.
On valuation the read is fair — an earnings multiple of 30.5, absent a reliable peer benchmark. The average analyst target implies 10.4% above today's level. Revenue is growing at 10.2% on a 4.9% profit margin. The 1.25% dividend yield looks covered by current payout levels.
Risk scores 8 out of 10, which is high for this asset class. With 30-day volatility of 37.1%, a beta of 1.37 and a maximum drawdown of 36.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to buy, carrying 4/10 conviction.

Top Market Events

Have you looked into how Quaker Chemical KWR performed internationally during the quarter ending June 2026?Quaker Chemical Corporation KWR target price: $221.Quaker Chemical’s latest analyst update comes with no changes to the existing price target, which keeps the...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 143.68
  • MACD momentum is positive

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 143.68
  • Analyst targets imply +10.4% versus the current price

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • Analyst targets imply +10.4% versus the current price
  • Revenue growth of +10.2%
  • P/E ratio of 30.5

Key Metrics & Analysis

Financial Health

Revenue Growth10.20%
Profit Margin4.95%
P/E Ratio30.5
ROE7.17%
ROA4.10%
Debt/Equity66.91
P/B Ratio2.1
Op. Cash Flow$131.2M
Free Cash Flow$129.9M

Technical Analysis

TrendBullish
RSI64.5
Support$137.18
Resistance$175.07
MA 20$156.29
MA 50$151.86
MA 200$143.68
MACDBullish
VolumeIncreasing
Fear & Greed Index94.82

Valuation

Fair Value$103.76
Target Price$187.57
Upside/Downside10.37%
GradeFair
TypeBlend
Dividend Yield1.25%

Risk Assessment

Beta1.37
Volatility37.05%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.